Aytu biopharma announces approval of adzenys xr-odt(r)manufacturing site transfer

U.s. food & drug administration approval of prior approval supplement enables transfer of adzenys production to contract manufacturer in 2023 upon completion of manufacturing transfer of adzenys xr-odt and cotempla xr-odt, company expects to improve adhd product margins by an estimated 15% englewood, co / accesswire / april 27, 2023 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, received u.s. food & drug administration ("fda") approval of the adzenys xr-odt® ("adzenys") prior approval supplement ("pas"). this approval enables the transfer of manufacturing of adzenys to the company's third-party manufacturer.
AYTU Ratings Summary
AYTU Quant Ranking